Clinical Needs Identification & Market analysis
IP landscape & Freedom to Operate
Prototyping & 3D printing
FMEA analysis & risk mitigation activities
Verification and validation testing
Regulatory submission management
Manufacturing transfer
Rigors increase in intensity based on predicate technologies or devices and the relative invasive nature of their use, adjacent to, in contact with, or invasive within the patient.
Take a look at a few of your GT peers working with GCMI.
More than two decades and hundreds of preclinical studies completed, GCMI remains an industry leader in medtech design, development, preclinical testing and bioskills training programs.
GCMI has dedicated, annual funding for medtech innovation at Georgia Tech, specifically for projects we believe have high potential for successful commercialization.
Scott Hollister, Patsy and Alan Dorris Endowed Chair in Pediatric Technology, Professor, BME
Hollister and his team of biomedical engineers collaborated with the Global Center for Medical Innovation (GCMI) so that GCMI and Children's Healthcare of Atlanta on Georgia's first 3D printed tracheal implant in a pediatric patient.
Omer Inan, Linda J. and Mark C. Smith Chair and Associate Professor, ECE
After an IV needle has been inserted into a vein, there are various factors that can cause it to leak, either just beneath the skin or even deeper, into surrounding tissues. This painful process of unintended leakage is called infiltration.
W. Hong Yeo, Associate Professor, Woodruff Faculty Fellow
Currently available digital stethoscopes are durable but expensive, bulky and heavy for pediatrics, not capable of continuously monitoring sounds and subject to cross contamination. Dr. Yeo'S wireless flexible technology flips the script.
By: Marty Jacobson with Paul Snyder Because clinicians have such an intimate knowledge of unmet clinical needs, hospitals are fertile ground for medtech innovations that improve value and outcomes. But bringing a technology or device to bear in clinical use, especially at any scale, works in much different, much more rigorous ways and paths…
Prologue – Eliminating a Surgical Never Event that Should not Exist Surgical instruments that emit high-intensity light coupled with human error are a leading cause of intraoperative fires and patient burns. The healthcare system refers to incidents like these as “never events” so they should never happen, right? But, survey results published in the Joint…
GCMI recently welcomed Georgia Tech President Angel Cabrera for an inside look at our work and its impact. Almost immediately after Angel Cabrera was named President of Georgia Tech in 2019, he led “more than 5,700 members of the Georgia Tech community [who] contributed to a new 10-year strategic plan that launched in November 2020.…
Fact: Atlanta enjoys assets critical to medtech innovation on par with those in hubs like Boston and the Bay Area. In abundance Atlanta has clinicians, hospitals, patients, universities including two medical schools, engineers, entrepreneurs, solutions providers and supporting state and municipal resources. We are also home for the Centers of Disease Control and Prevention. …
Medtech and life science innovation is intensely rigorous. It requires high levels of acumen and proficiency in multiple disciplines. It can also be immensely capital intensive. Tiffany Wilson founded Atlanta’s Global Center for Medical Innovation (GCMI) in 2012 to help medtech innovators de-risk their technologies, increasing their odds of successful commercialization and positive patient…
New medical technologies for pediatric care face difficult hurdles to commercialization, especially industry investment, due to relatively small market size and the quickly shifting nature of pediatric anatomy. In many cases, compassionate or “expanded use” regulatory pathways are needed to make new technologies available for clinical use in pediatric patients. In December, GCMI Research…
We've got some funding for promising medical technologies.
GCMI has dedicated, annual funding for medtech innovation at Georgia Tech, specifically for projects we believe have high potential for successful commercialization, follow-on funding and improved patient outcomes. Funded projects are selected by GCMI leadership inclusive of consultation with the board of directors.
You've found a clinical partner. Now what?
New medical technologies are subject to the significant, necessary rigors applied by regulatory bodies and, ultimately, market forces. Those rigors increase in intensity based on predicate technologies or devices and the relative invasive nature of their use, adjacent to, in contact with, or invasive within the patient.
Phase Zero: The place to start for your new medical technology or idea.
Doing the right things early and following a rigorous phase gated process can substantially increase the likelihood of milestone achievement at any point in a technology’s commercialization pathway.
